No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CSTL250117C12500
- 0.00
- 0.000.00%
15min DelayClose Dec 26 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover263.73%IV-53.87%PremiumJan 17, 2025Expiry Date14.60Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9375Delta0.0071Gamma1.78Leverage Ratio-0.0507Theta0.0060Rho1.67Eff Leverage0.0081Vega
Intraday
- 5D
- Daily
No Data
News
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40
Analysts' Top Healthcare Picks: Lifecore Biomedical (LFCR), Castle Biosciences (CSTL)
Express News | Castle Biosciences Inc: Expects to Launch Pipeline Test by End of 2025
Castle Biosciences Highlights Progress for Its Pipeline Atopic Dermatitis Gene Expression Profile Test
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)